{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:26Z","timestamp":1791312086566,"version":"4.3.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ucl.2025.09.001","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:23:45Z","timestamp":1761654225000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prostate Cancer Screening"],"prefix":"10.1016","volume":"53","author":[{"given":"Omri","family":"Nativ","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabika","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Cuvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanoj","family":"Punnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.001_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1055-9965.EPI-22-1038","article-title":"Estimating the number of men living with metastatic prostate cancer in the United States","volume":"32","author":"Devasia","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10437","key":"10.1016\/j.ucl.2025.09.001_bib3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.001_bib4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11764-023-01509-8","article-title":"Health-related quality of life among prostate cancer survivors with metastatic disease and non-metastatic disease and men without a cancer history in the USA","volume":"19","author":"Zheng","year":"2025","journal-title":"J Cancer Surviv"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075595","article-title":"Early detection of clinically significant prostate cancer: protocol summary and statistical analysis plan for the ProScreen randomised trial","volume":"14","author":"Nevalainen","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.ucl.2025.09.001_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11912-008-0080-1","article-title":"Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice","volume":"10","author":"Sarvis","year":"2008","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jnci\/djp001","article-title":"Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context","volume":"101","author":"Draisma","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-020-06942-x","article-title":"Discrimination between clinically significant and insignificant prostate cancer with apparent diffusion coefficient: a systematic review and meta-analysis","volume":"20","author":"Meyer","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ucl.2025.09.001_bib9","unstructured":"National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: prostate cancer early detection. version 2.2025."},{"key":"10.1016\/j.ucl.2025.09.001_bib10","unstructured":"American Urological Association; Society of Urologic Oncology. Early detection of prostate cancer: AUA\/SUO guideline. 2023."},{"issue":"18","key":"10.1016\/j.ucl.2025.09.001_bib11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: final recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12301-021-00129-x","article-title":"Clinical diagnosis of prostate cancer using digital rectal examination and prostate-specific antigen tests: a systematic review and meta-analysis of sensitivity and specificity","volume":"27","author":"Okpua","year":"2021","journal-title":"Afr J Urol"},{"issue":"10071","key":"10.1016\/j.ucl.2025.09.001_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","article-title":"EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease","volume":"59","author":"Heidenreich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.001_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d7894","article-title":"Short-term outcomes of prostate biopsy in men tested for cancer by prostate-specific antigen: prospective evaluation within ProtecT study","volume":"344","author":"Rosario","year":"2012","journal-title":"BMJ"},{"issue":"740","key":"10.1016\/j.ucl.2025.09.001_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3399\/bjgp24X736677","article-title":"Is the digital rectal exam any good as a prostate cancer screening test?","volume":"74","author":"Kirby","year":"2024","journal-title":"Br J Gen Pract"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.urology.2004.12.021","article-title":"Digital rectal examination is barrier to population-based prostate cancer screening","volume":"65","author":"Nagler","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.001_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12301-024-00449-8","article-title":"Digital rectal exam in prostate cancer screening: a critical review of the ERSPC rotterdam study","volume":"30","author":"Bouras","year":"2024","journal-title":"Afr J Urol"},{"issue":"22","key":"10.1016\/j.ucl.2025.09.001_bib20","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ucl.2025.09.001_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","article-title":"Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends","volume":"94","author":"Etzioni","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.001_bib22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"ERSPC investigators. Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature","volume":"68","author":"F\u00fctterer","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.001_bib24","first-page":"512","article-title":"The detection of significant prostate cancer is correlated with the prostate imaging reporting and data system (PI-RADS) in patients with PIRADS 3 lesions","volume":"69","author":"Cash","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib25","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.juro.2016.06.079","article-title":"Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR","volume":"196","author":"Rosenkrantz","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.001_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.21037\/tau.2017.01.13","article-title":"Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer","volume":"6","author":"Hutchinson","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib27","first-page":"217","article-title":"Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy","volume":"25","author":"Wang","year":"2023","journal-title":"Asian J Androl"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.001_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","article-title":"Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the g\u00f6teborg randomized population-based prostate cancer screening trial","volume":"68","author":"Arnsrud Godtman","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.001_bib29","article-title":"Urologists\u2019 and general practitioners\u2019 knowledge, beliefs and practice relevant for opportunistic prostate cancer screening: a PRISMA-Compliant systematic review","volume":"11","author":"Estevan-Ortega","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib30","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.001_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju292","article-title":"Prostate cancer mortality in areas with high and low prostate cancer incidence","volume":"106","author":"Pinsky","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.001_bib33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.001_bib35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"CAP trial group. Effect of a low-intensity PSA-Based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"issue":"7593","key":"10.1016\/j.ucl.2025.09.001_bib36","first-page":"576","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis","volume":"334","author":"Lilja","year":"2007","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib37","first-page":"1234","article-title":"Free PSA and risk of clinically significant and fatal prostate cancer in the PLCO trial","volume":"209","author":"Guichard","year":"2023","journal-title":"J Urol"},{"issue":"19","key":"10.1016\/j.ucl.2025.09.001_bib38","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib39","first-page":"45","article-title":"Incorporation of free-to-total PSA ratio improves discrimination for clinically significant prostate cancer in men with low total PSA","volume":"133","author":"Vickers","year":"2024","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.001_bib40","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","article-title":"Use of prostate health index for detection of aggressive prostate cancer: a prospective multicenter study","volume":"193","author":"Loeb","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib41","first-page":"e25","article-title":"Prostate cancer detection using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging","volume":"66","author":"Nordstr\u00f6m","year":"2014","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.ucl.2025.09.001_bib42","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate cancer diagnosis (PRECISION): a randomised, non-inferiority trial","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.001_bib43","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.17942","article-title":"Comparison of MR\/ultrasound fusion\u2013guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer","volume":"313","author":"Siddiqui","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib44","article-title":"Clinical and imaging predictors of false-positive and false-negative results in prostate multiparametric MRI using PI-RADS version 2. Radiol imaging","volume":"7","author":"Salka","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40644-020-00351-w","article-title":"Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study","volume":"20","author":"Hietikko","year":"2020","journal-title":"Cancer Imaging"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.001_bib46","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.001_bib47","first-page":"923","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"63","author":"Castro","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib48","first-page":"1005","article-title":"Disparities in prostate cancer: African-American men","volume":"22","author":"Rebbeck","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.001_bib49","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men\u2014results of the first screening round of the PROBASE trial","volume":"150","author":"Arsov","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ucl.2025.09.001_bib50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2024.01.017","article-title":"Prostate cancers in the prostate-specific antigen interval of 1.8\u20133 ng\/ml: results from the G\u00f6teborg-2 prostate cancer screening trial","volume":"86","author":"M\u00f6ller","year":"2024","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.001_bib51","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54577","article-title":"Repeated prostate cancer screening using prostate-specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3-MRI randomized clinical trial","volume":"7","author":"Nordstr\u00f6m","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.001_bib53","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"ProScreen Trial Investigators. Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.001_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.euo.2023.03.009","article-title":"An evaluation of screening pathways using a combination of magnetic resonance imaging and prostate-specific antigen: results from the IP1-PROSTAGRAM study","volume":"6","author":"Eldred-Evans","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib55","first-page":"223","article-title":"Decipher genomic classifier: prognostic utility in prostate cancer","volume":"78","author":"Cooperberg","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib56","first-page":"327","article-title":"A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy","volume":"205","author":"Cullen","year":"2021","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.001_bib57","first-page":"539","article-title":"Integrating multi-omic biomarkers in prostate cancer risk stratification","volume":"20","author":"Sartor","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib58","article-title":"Artificial intelligence for prostate MRI: recent advances and future directions","volume":"4","author":"Gaur","year":"2022","journal-title":"Radiology: AI"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.001_bib59","first-page":"849","article-title":"Clinical implications of artificial intelligence-assisted MRI interpretation in prostate cancer","volume":"7","author":"Mehralivand","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.001_bib60","first-page":"151","article-title":"Revisiting the definition of clinically significant prostate cancer","volume":"37","author":"Vickers","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.001_bib61","first-page":"61","article-title":"Genetic risk score stratification for prostate cancer screening","volume":"113","author":"Huynh-Le","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2025.09.001_bib62","article-title":"Personalised screening for prostate cancer: incorporating polygenic risk and family history","volume":"380","author":"Pashayan","year":"2023","journal-title":"BMJ"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:04:42Z","timestamp":1765289082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0094014325000849"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Screening","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}